Skip to main content

Noci Darlene's Form 4 filing

Nuvalent, Inc. (NUVL) · filed Mar 25, 2024

Accession no.
0000950170-24-035977
Filed
Mar 25, 2024
Trade date
Mar 22, 2024
Filing delay
3 days
Rule 10b5-1 plan
Checked

This filing lists 5 non-derivative transactions and 2 derivative transactions. Open-market sales total $1.55M. It was filed 3 days after the trade.

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
OwnerRelationship to the company
Noci DarleneCIK 0001862148Officer (Chief Development Officer)

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

Non-derivative transactions
Trade dateSecurityTransactionSharesPriceValueShares afterOwnershipFlags
Mar 22, 2024Class A Common StockMOption exerciseAcquired+10,000$1.08+$10,80043,300Direct
Mar 22, 2024Class A Common StockMOption exerciseAcquired+10,000$14.40+$144,00053,300Direct
Mar 22, 2024Class A Common StockSSaleDisposed−13,100$77.25F2−$1,011,97540,200Direct
Mar 22, 2024Class A Common StockSSaleDisposed−6,300$77.94F3−$491,02233,900Direct
Mar 22, 2024Class A Common StockSSaleDisposed−600$78.72F4−$47,23233,300Direct

Derivative securities (Table II)

Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.

Derivative transactions
Trade dateSecurityTransactionUnderlying sharesUnit priceValueHeld afterOwnershipFlags
Mar 22, 2024Class A Common StockMOption exerciseDisposed−10,000$0.00$036,201Direct
Mar 22, 2024Class A Common StockMOption exerciseDisposed−10,000$0.00$034,161Direct

Footnotes and remarks

Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.

F2

The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $76.62 to $77.61, inclusive. The reporting person undertakes to provide to the staff of the Securities and Exchange Commission, Nuvalent, Inc. or any security holder of Nuvalent, Inc., upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2) through (4) of this Form 4.

Referenced by the price of 1 transaction in Table I.

F3

The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $77.62 to $78.54, inclusive.

Referenced by the price of 1 transaction in Table I.

F4

The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $78.64 to $78.83, inclusive.

Referenced by the price of 1 transaction in Table I.

Read the full filing on SEC EDGAR (opens in a new tab)